A Phase 3 interventional study of tauroursodeoxycholic and ursodeoxycholic acid in Cholestatic Liver Disease, sponsored by Beijing Trendful Kangjian Medical Information Consulting Limited Company. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2014-03-24.
Sponsored by Beijing Trendful Kangjian Medical Information Consulting Limited Company · Phase 3, Interventional, and Treatment
Though ursodeoxycholate acid (UDCA) is the well known effective therapy for PBC,clinical effectiveness of UDCA may be limited by its poor absorption and extensive biotransformation.The more hydrophillic bile acid tauroursodeoxycholate (TUDCA) is the active ingredients of UDCA,and has been approved by state food and drug administration in China for treatment of cholesterol stones.So it is necessary to verify the efficacy and safety of TUDCA in the treatment of adult primary biliary cirrhosis. In this randomized, double-blinded, double -dummy, parallel-controlled and multicenter clinical trial, we detect the proportion of patients who had AKP decline more than 25% as the primary outcome;decline of ALP,total bilirubin, GGT,ALT and AST as secondary outcomes after patients were treated with TUDCA or UDCA for 24 weeks.
This is a double-blind, randomized, parallel controlled, multicenter, clinical trial. Subjects inclusion by randomization after passing the screening, continuous administration the test drug (Taurolite) or control drug (Ursofalk) treatment for 24 weeks. Compare the safety and efficacy of Taurolite vs Ursofalk.
At the end of the double-blind period，enroll 100 subjects from both two group randomly ,for a consecutive treatment use TUDCA up to 24 weeks. Further evaluate the efficacy and safety of tauroursodeoxycholic acid (TUDCA) in the treatment of adult primary biliary cirrhosis (PBC) for a long time up to one year. Also evaluate the regimen's efficacy and safety that udca take placed by TUDCA in the treatment of adult primary biliary cirrhosis (PBC) for the patients who use udca treatment for 24 weeks.
2,081 studies on the registry are indexed under Liver Diseases; 390 are open to participants now.
This study's enrollment of 199 is above the median of 50 across 1,323 interventional studies indexed under Liver Diseases.
Browse Liver Diseases studies →This is the only study on the registry with Beijing Trendful Kangjian Medical Information Consulting Limited Company as lead sponsor.
Counted across the registry records on this site, refreshed daily.
1 Ages Eligible for Study: 18 Years to 70 Years
2 Alkaline phosphatase (ALP) ≥ 2 times the Upper Limits of Normal (ULN);
3 Anti mitochondrial antibody (AMA) positive and / or anti-mitochondrial antibody subtype M2 (AMA-M2) positive; if the AMA and AMA-M2 were negative, need liver biopsy confirmed pathological changes in PBC.
Exclusion Criteria:
1．in the 3 months before screening received UDCA, hormones, immunosuppressive therapy;
2．with extrahepatic biliary obstruction;
3．accompanied by hepatitis B virus (HBV) and hepatitis C virus (HCV) infection;
4．laboratory screening examination :
5．patients with esophageal variceal or bleeding, ascites, hepatic encephalopathy or other evidence of hepatic decompensation;
6．diagnosed with liver cancer, suspected to have liver cancer, AFP > 100ng/ml. As the AFP in 2 times the upper limit of normal to 100ng/ml, need re-check in 2 weeks, if their AFP > 100ng/ml can not be included
7．body mass index >28 (Kg/m2);
8．alcohol or drug abusers within the recent year;
9．there is a serious heart, lung, kidney, digestive, nervous, mental disease, autoimmune diseases or malignant tumor
10．drug-induced liver injury;
12． are unable or unwilling to provide informed consent or fails to comply with the test requirements;
13．pregnant, lactating women.
tauroursodeoxycholic acid, 750mg , divided into three times, each time 250mg, oral administration, after meal
Drug: tauroursodeoxycholic
control arm: ursodeoxycholic acid, 750mg ,divided into three times, each time 250mg, oral administration, after meal
Drug: ursodeoxycholic acid
Testing arm: tauroursodeoxycholic acid, 750mg , divided into three times, each time 250mg, oral administration, after meal
Also known as: TUDCA, Taurolite
ursodeoxycholic acid, 750mg ,divided into three times, each time 250mg, oral administration, after meal
Also known as: UDCA, Ursofalk
Efficiency is defined as the patients composition whose ALP level of serum decreased more than 25% compared to baseline at treatment for 24 weeks.
After 24 weeks of treatment, calculate the rate of patients whose ALP level of serum ALP decreased more than 25% compared to the baseline. After 48 weeks of treatment, calculate the rate of patients whose ALP level of serum ALP decreased more than 40% compared to the baseline.
Time frame: 48 weeks
The change of laboratory parameters about liver function
1. after 24 weeks of treatment, the serum level ALP decreased compared with baseline. 2. after 24 weeks of treatment, the serum bilirubin level decreased compared with baseline. 3. after 24 weeks of treatment, the serum level of GGT decreased compared with baseline. 4. after 24 weeks of treatment, serum ALT, AST levels decreased compared to baseline. 5. after 48 weeks of treatment, the serum level ALP decreased compared with 24 weeks. 6. after 48 weeks of treatment, the serum level ALP decreased compared with baseline. 7. after 48 weeks of treatment, the serum bilirubin level decreased compared with 24 weeks. 8. after 48 weeks of treatment, the serum level of GGT decreased compared with 24 weeks. 9. after 48 weeks of treatment, serum ALT, AST levels decreased compared to 24 weeks.
Time frame: 48 weeks
This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.